viewCallitas Health Inc

M Pharmaceutical's transformation continues apace

Third quarter results were largely academic, as the pre-revenue company is still in a transitional stage.

M Pharmaceutical's target markets are enormous and growing

Pre-revenue diabetes and obesity specialist M Pharmaceutical's (CNSX:MQ, OTCMKTS:MPHMF) third quarter results showed the signs of the company's vigorous transformation.

It is less than a year since the former First Sahara Energy changed tack to focus on the pharmaceutical and biomedical device markets, with a particular onus on tackling diabetes, obesity and other gastroenterological indications, and the company certainly has not let the grass grow under its feet, signing a succession of deals.

The need to do all that due diligence is reflected in consulting fees in the third quarter, which rose to C$434,590 from C$107,789 the year before, which was a major factor in the loss before exceptional items widening to C$599,731 from C$205,348 a year earlier.

The company also took a paper-based loss of C$132,307 on a change in the fair value of its investments.

Quick facts: Callitas Health Inc

Price: - CAD

Market: CSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company...



M Pharmaceutical boss looking forward to a great 2017 and 2018

Gary Thompson is at the helm of drug company M Pharmaceutical, which he describes as a "small company with big ideas". Talking to Proactive, he said that when finished soon with its acquisition of Cincinnati-based 40 J’s, it will have a current revenue stream from about seven different...

on 8/2/17

2 min read